Indivior PLC (LON:INDV) has said its RECOVER study found that 75% of patients with opioid addiction were abstinent from illicit opioids use a year after receiving 12 monthly injections of the company's Sublocade treatment.
Reporting additional data from the study at the 50th ASAM Annual Conference, the FTSE 250-listed firm pointed out that patients self-reported their abstinence, with the results later confirmed by urine drug screen.
READ: Indivior launches cheap version of Suboxone with generics now free to hit the market
Indivior’s chief scientific officer, Christian Heidbreder commented: "RECOVER is assessing real-world outcomes in patients for up to two years after they completed our clinical phase 3 Sublocade study.
"We have invested in this research to help answer questions about how medication-assisted treatment can help patients with opioid use disorder maintain recovery in their communities and live healthier lives."
The group also said an additional 18-month safety study among Sublocade-treated patients reported "no new safety issues".
It added that data from this second study also supported the efficacy of Sublocade and its impact on retaining patients with opioid use disorder in treatment.